Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 166Carboplatin 132Cisplatin 81Paclitaxel 78Gemcitabine 77Pemetrexed 72Bevacizumab 63Docetaxel 54Fluorouracil 49Oxaliplatin 48Dexamethasone 46durvalumab 43atezolizumab 39Leucovorin 39130-nm albumin-bound paclitaxel 39Capecitabine 37Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Prednisone 28Lenalidomide 28enzalutamide 27pomalidomide 25Letrozole 25Irinotecan 25daratumumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Histamine Antagonists × 30 days × Clear all
NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06305754 2026-05-29

MK-2870-009

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
520 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡